Small Molecules

17 Jun 2017 Galera Therapeutics Completes Enrollment in Phase 2b Clinical Trial with Lead Compound GC4419 for Treatment of Oral Mucositis
17 Jun 2017 Cerveau Technologies, Inc. Announces FDA Acceptance of Investigational New Drug (IND) for Tau Imaging Agent MK-6240
15 Jun 2017 RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA™) for H. pylori Infection
15 Jun 2017 Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN
14 Jun 2017 Aldeyra Therapeutics Announces Results from Allergic Conjunctivitis Phase 2b Clinical Trial and Plans for Phase 3 Clinical Testing
14 Jun 2017 Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus
14 Jun 2017 ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of Novel Autoimmune Disease Drug
14 Jun 2017 Modra Pharmaceuticals Announces Start of Phase II Study for its Lead Oral Chemotherapy in Patients with Metastatic Prostate Cancer
14 Jun 2017 Pimodivir Alone or in Combination with Oseltamivir Demonstrated a Significant Reduction in Viral Load in Adults with Influenza A
14 Jun 2017 Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients
14 Jun 2017 Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durable Pain Relief with CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain
13 Jun 2017 InMed Announces Agreement to Advance a Topical Formulation of INM-750
13 Jun 2017 ENYO Pharma SA Announces Successful Completion of EYP001 First in Man Phase 1 Study
13 Jun 2017 Threshold Pharmaceuticals Announces First Patient Dosed in Immunotherapy Clinical Trial of Evofosfamide and Ipilimumab
13 Jun 2017 INVOKANA® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction and Stroke in the CANVAS Program
12 Jun 2017 Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder
12 Jun 2017 Foamix Announces Dosing of First Patient in Phase 3 Rosacea Clinical Trials for FMX103 Minocycline Foam 1.5%
12 Jun 2017 Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
12 Jun 2017 Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment
12 Jun 2017 Jardiance® (empagliflozin) tablets to be studied in chronic kidney disease
12 Jun 2017 Probiodrug announces encouraging results of the Phase 2a SAPHIR Study
12 Jun 2017 Chi-Med Submits New Drug Application to CFDA for Fruquintinib in Advanced Colorectal Cancer
12 Jun 2017 vTv Therapeutics Presents Data Highlighting Further Potential of TTP273 at American Diabetes Association 77th Scientific Sessions
11 Jun 2017 Zynerba Pharmaceuticals Achieves Target Enrollment in Exploratory Phase 2 Trial of ZYN002 in Fragile X Syndrome
11 Jun 2017 Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association’s 77th Annual Scientific Sessions

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing